Type 2 diabetes: principles of pathogenesis and therapy

被引:1781
作者
Stumvoll, M
Goldstein, BJ
van Haeften, TW
机构
[1] Univ Med Ctr Utrecht, Dept Internal Med G02 228, NL-3508 GA Utrecht, Netherlands
[2] Univ Leipzig, Dept Med 3, D-7010 Leipzig, Germany
[3] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA
关键词
D O I
10.1016/S0140-6736(05)61032-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus has become an epidemic, and virtually no physician is without patients who have the disease. Whereas insulin insensitivity is an early phenomenon partly related to obesity, pancreas beta-cell function declines gradually over time already before the onset of clinical hyperglycaemia. Several mechanisms have been proposed, including increased non-esterified fatty acids, inflammatory cytokines, adipokines, and mitochondrial dysfunction for insulin resistance, and glucotoxicity, lipotoxicity, and amyloid formation for beta-cell dysfunction. Moreover, the disease has a strong genetic component, but only a handful of genes have been identified so far: genes for calpain 10, potassium inward-rectifier 6.2, peroxisome proliferator-activated receptor gamma, insulin receptor substrate-1, and others. Management includes not only diet and exercise, but also combinations of anti-hyperglycaemic drug treatment with lipid-lowering, antihypertensive, and anti platelet therapy.
引用
收藏
页码:1333 / 1346
页数:14
相关论文
共 156 条
  • [21] The STOP-NIDDM Trial -: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance:: rationale, design, and preliminary screening data
    Chiasson, JL
    Gomis, R
    Hanefeld, M
    Josse, RG
    Karasik, A
    Laakso, M
    [J]. DIABETES CARE, 1998, 21 (10) : 1720 - 1725
  • [22] Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
    Chiasson, JL
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. LANCET, 2002, 359 (9323) : 2072 - 2077
  • [23] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [24] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [25] Colwell John A, 2004, Diabetes Care, V27 Suppl 1, pS72
  • [26] Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: Examples from studies of the calpain-10 gene
    Cox, NJ
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (20) : 2301 - 2305
  • [27] Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus
    Cusi, K
    Consoli, A
    DeFronzo, RA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (11) : 4059 - 4067
  • [28] Dandona Paresh, 2003, Clin Cornerstone, VSuppl 4, pS13
  • [29] Failure of adipocyte differentiation causes type II diabetes mellitus?
    Danforth, E
    [J]. NATURE GENETICS, 2000, 26 (01) : 13 - 13
  • [30] Therapeutic strategies based on glucagon-like peptide 1
    Deacon, CF
    [J]. DIABETES, 2004, 53 (09) : 2181 - 2189